Search clinical trials for: Dalantercept and axitinib

Total 269668 results

Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma

United States
Pfizer

Completed

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Neoplasms

Poland, United States, Spain
Peking University Cancer Hospital & Institute

Unknown

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624)

Advanced Mucosal Melanoma

China
Pfizer

Completed

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Carcinoma, Renal Cell

United States, Spain, Japan, Germany, Czechia, Russian Federation
Chinese University of Hong Kong

Completed

Nasopharyngeal Carcinoma (NPC) Axitinib

Recurrent or Metastatic NPC

Hong Kong
Pfizer

Completed

Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

Melanoma | Skin Neoplasms

United States, France
Pfizer

Completed

Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer

Lung Neoplasms | Carcinoma, Non-small Cell Lung

United States, Germany
University of Wisconsin, Madison
Pfizer

Completed

Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib

Solid Malignancies | Metastatic Castrate-resistant Prostate Cancer

United States
Spanish Cooperative Group for the Treatment of...

Terminated

Axitinib as Maintenance Treatment in Patients With Metastatic CRC (TTD-11-01)

Colorectal Carcinoma

Spain
Assistance Publique - Hôpitaux de Paris
Pfizer

Completed

Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN) (AXIPAN)

cT2a N0NxM0 Renal Tumor

France
Akeso

Recruiting

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma | First-line Treatment

China
Kidney Cancer Research Bureau

Completed

Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors (FavorAx)

Carcinoma, Renal Cell | Clear Cell Renal Cell Carcinoma

Russian Federation
Pfizer

Completed

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Kidney Neoplasms | Carcinoma, Renal Cell

United States
Bart Neyns
Pfizer

Completed

A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (AxiGII)

Glioblastoma Multiforme

Belgium
Li Zhang, MD

Not yet recruiting

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Hepatobiliary Neoplasm | Liver Neoplasm | Biliary Tract Neoplasms

China
Pfizer

Completed

Axitinib Pharmacokinetics in Chinese Healthy Volunteers

Healthy Volunteers

China
Hongqian Guo

Active, not recruiting

A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC

Neoadjuvant Therapy

China
National Cancer Institute (NCI)

Completed

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Pfizer

Completed

A Study In Patients With Advanced Solid Tumor

Neoplasms

Japan
University Health Network, Toronto
Pfizer

Completed

Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma (AXITINIB)

Hepatocellular Carcinoma

Canada
Pfizer

Completed

Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

Carcinoma

Japan
Pfizer

Completed

Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012

Carcinoma, Renal Cell

United States, France, Germany
Pfizer

Completed

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom
University of Michigan Rogel Cancer Center

Completed

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer (AXUS)

Colorectal Carcinoma

France
Pfizer

Completed

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML)

United States
Pfizer

Completed

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Kidney Neoplasms

Korea, Republic of, United States, Canada, Spain, Italy, United Kingdom, China, Singapore, Slovakia, France, Japan, Australia, Germany, Taiwan, Brazil, Russian Federation, India, Poland, Austria, Greece, Ireland, Sweden
Pfizer

Terminated

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Czechia
University of California, San Diego
The Cleveland Clinic

Unknown

Prior Axitinib as a Determinant of Outcome of Renal Surgery (PADRES)

Clear Cell Renal Cell Carcinoma

United States
Incyte Corporation

Recruiting

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United Kingdom, Italy, France, Belgium, Hungary
X4 Pharmaceuticals

Completed

Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States, Korea, Republic of
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Advanced Melanoma

China
Pfizer

Completed

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Kidney Neoplasms

United States, China, Malaysia, India, Taiwan, Russian Federation, Mexico, Bosnia and Herzegovina, South Africa, Bulgaria, Chile, Philippines, Romania, Ukraine
Lynkcell Europe

Available

An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)

Kidney Cancer | Clear Cell Kidney Cancer | Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations
Memorial Sloan Kettering Cancer Center
Pfizer; National Comprehensive Cancer Network

Completed

Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
ZHOU FANGJIAN
Pfizer

Recruiting

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Renal Cell Carcinoma | Neoadjuvant

China
Pfizer

Completed

A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers

Healthy Volunteers

Singapore
Scottish Clinical Trials Research Unit
Pfizer

Completed

Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion (NAXIVA)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Non-metastatic Renal Cell Carcinoma

United Kingdom
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...

United States
Tracon Pharmaceuticals Inc.

Terminated

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Hungary, Czechia, United Kingdom
Skogli Health and Rehabilitation Center

Completed

Effects of a Single Dose of Brazil Nuts on Blood Lipids

Cholesterol Level, High

Norway
Clearside Biomedical, Inc.

Completed

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Neovascular Age-related Macular Degeneration

United States
Pfizer

Completed

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

France, Belgium, United States, Taiwan, Hong Kong, United Kingdom, Germany, Italy, China, Hungary, Japan, Slovakia, Korea, Republic of
Peking University Cancer Hospital & Institute

Recruiting

Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma

Mucosal Melanoma

China
Pfizer

Completed

Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

Renal Cell Carcinoma

Japan

Search clinical trials for: Dalantercept and axitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations